[1]肖若薇,朱 贺,李 薇,等.注射用脑蛋白水解物（Ⅰ）与（Ⅱ）治疗脑梗死恢复期患者的医疗费用和住院天数比较[J].医学信息,2022,35(14):95-98.[doi:10.3969/j.issn.1006-1959.2022.14.022]
　XIAO Ruo-wei,ZHU He,LI Wei,et al.Comparison of Medical Expenses and Hospitalization Days Between Cerebroprotein Hydrolysate (Ⅰ) and (Ⅱ) Injection in Patients with Cerebral Infarction During Convalescence[J].Medical Information,2022,35(14):95-98.[doi:10.3969/j.issn.1006-1959.2022.14.022]
点击复制

注射用脑蛋白水解物（Ⅰ）与（Ⅱ）治疗脑梗死恢复期患者的医疗费用和住院天数比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年14期
页码:
95-98
栏目:
论著
出版日期:
2022-07-15

文章信息/Info

Title:
Comparison of Medical Expenses and Hospitalization Days Between Cerebroprotein Hydrolysate (Ⅰ) and (Ⅱ) Injection in Patients with Cerebral Infarction During Convalescence
文章编号:
1006-1959（2022）14-0095-04
作者:
肖若薇; 朱 贺; 李 薇; 等
（1.北京大学医药管理国际研究中心，北京 100191；2.北京大学药学院，北京 100191）
Author(s):
XIAO Ruo-wei; ZHU He; LI Wei; et al.
(1.International Research Center for Medicinal Administration,Peking University,Beijing 100191,China;2.School of Pharmaceutical Sciences,Peking University,Beijing 100191,China)
关键词:
脑梗死恢复期; 注射用脑蛋白水解物; 医疗费用; 住院天数
Keywords:
Cerebral infarction recovery period; Cerebroprotein hydrolysate injection; Medical expenses; Hospitalization days
分类号:
R956
DOI:
10.3969/j.issn.1006-1959.2022.14.022
文献标志码:
A
摘要:
目的 比较注射用脑蛋白水解物（Ⅰ）与（Ⅱ）治疗脑梗死恢复期患者的医疗费用和住院天数的差异。方法 通过河北省某三级医院2017年3月25日-2019年3月26日合理用药调研数据选取206例脑梗死恢复期患者，根据使用的注射用脑蛋白水解物类型分成注射用脑蛋白水解物（Ⅰ）组和注射用脑蛋白水解物（Ⅱ）组，各103例，比较两组的医疗费用和住院天数。结果 两组次均处方费用、次均床位费、次均护理费及次均中药费比较，差异无统计学意义（P＞0.05）；注射用脑蛋白水解物（Ⅱ）组次均住院总费用、次均治疗费、次均检查费、次均其他费用及次均住院天数少于注射用脑蛋白水解物（Ⅰ）组，差异有统计学意义（P＜0.05）。结论 使用注射用脑蛋白水解物（Ⅰ）与（Ⅱ）治疗的脑梗死恢复期患者在次均处方费用方面基本一致，但使用注射用脑蛋白水解物（Ⅱ）治疗的患者的次均住院总费用较低，次均住院天数较短。
Abstract:
Objective To compare the differences of medical expenses and hospitalization days between injection of cerebroprotein hydrolysate (Ⅰ) and (Ⅱ) in patients with cerebral infarction during convalescence.Methods A total of 206 patients with cerebral infarction in recovery period were selected from the survey data of rational drug use in a tertiary hospital in Hebei Province from March 25, 2017 to March 26, 2019. According to the type of brain protein hydrolysate used for injection, the patients were divided into injection brain protein hydrolysate (Ⅰ) group and injection brain protein hydrolysate(Ⅱ) group, with 103 cases in each group. The medical costs and hospitalization days of the two groups were compared.Results There was no significant difference in prescription cost, bed cost, nursing cost and Chinese medicine cost between the two groups (P>0.05). The total cost of hospitalization, the average treatment cost, the average examination cost, the average other cost and the average length of stay in the injection brain protein hydrolysate (Ⅱ) group were less than those in the injection brain protein hydrolysate (Ⅰ) group, and the difference was statistically significant (P<0.05).Conclusion The average prescription costs of patients with cerebral infarction at recovery stage treated with injection of cerebroprotein hydrolysates (Ⅰ) and (Ⅱ) are basically the same, but the average hospitalization costs of patients treated with injection of cerebroprotein hydrolysates (Ⅱ) are lower and the average hospitalization days are shorter.

参考文献/References:

[1]章薇,娄必丹,李金香,等.中医康复临床实践指南·缺血性脑卒中（脑梗死）[J].康复学报,2021,31(6):437-447. [2]《中国脑卒中防治报告》编写组.《中国脑卒中防治报告2019》概要[J].中国脑血管病杂志,2020,17(5):272-281. [3]GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2018,392(10159):1789-1858.[4]Al-Qazzaz NK,Ali SH,Ahmad SA,et al.Cognitive impairment and memory dysfunction after a stroke diagnosis：a post-stroke memory assessment[J].Neuropsychiatr Dis Treat,2014,10:1677-1691.[5]刘倩,付本升,钟毓贤,等.奥拉西坦联合脑蛋白水解物治疗脑卒中后认知功能障碍的临床疗效及对血清Hcy、hs-CRP水平的影响[J].广西医科大学学报,2017,34(12):1748-1751. [6]Mijajlovic MD,Pavlovic A,Brainin M,et al.Post-stroke dementia - a comprehensive review[J].BMC Med,2017,15(1):11.[7]汪凯,董强,郁金泰,等.卒中后认知障碍管理专家共识2021[J].中国卒中杂志,2021,16(4):376-389.[8]何馨,何继明,张丹,等.注射用脑蛋白水解物治疗急性缺血性脑病的药物经济学评价[J].中国药物经济学,2017,12(12):14-19. [9]Bornstein NM,Guekht A,Vester J,et al.Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials[J].Neurol Sci,2018,39(4):629-640.[10]Charlson ME,Pompei P,Ales KL,et al.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J].J Chronic Dis,1987,40(5):373-383.[11]陈强.高级计量经济学及Stata应用（第二版）[M].北京:高等教育出版社,2014:542-555．[12]陈新谦,金有豫,汤光.新编药物学[M].北京:人民卫生出版社,2018:392.[13]劳荣巨,冯凤芳,李伟恩,等.520例住院患者注射用脑蛋白水解物应用合理性分析[J].中国医院用药评价与分析,2018,18(5):684-686,690.[14]Stepanichev M,Onufriev M,Aniol V,et al.Effects of cerebrolysin on nerve growth factor system in the aging rat brain[J].Restor Neurol Neurosci,2017,35(6):571-581. [15]王欣蕾,张雪,岳赞,等.注射用脑蛋白水解物(Ⅱ)对急性脑梗死患者的临床疗效观察[J].脑与神经疾病杂志,2018,26(9):534-538.[16]李书超,罗红艳.联合应用脑蛋白水解物和醒脑静对急性脑梗死患者神经功能的作用[J].吉林医学,2018,39(3):513-514.[17]Guan X,Wang Y,Kai G,et al.Cerebrolysin Ameliorates Focal Cerebral Ischemia Injury Through Neuroinflammatory Inhibition Via CREB/PGC-1α Pathway[J].FrontPharmacol,2019,10:1245. [18]Zhang L,Chopp M,Wang C,et al.Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke[J].J Neurol Sci,2019,398:22-26.[19]Zhang L,Chopp M,Lu M,et al.Demonstration of therapeutic window of Cerebrolysin in embolic stroke: A prospective, randomized, blinded, and placebo-controlled study[J].Int J Stroke,2017,12(6):628-635.[20]Liu Z,Wang W,Huang T,et al.CH(Ⅱ),a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease[J].PLoS One,2019,14(9):e0222757.

更新日期/Last Update: 1900-01-01